Literature DB >> 2009248

Further learnings from the European Working Party on High Blood Pressure in the Elderly (EWPHE) study: focus on systolic hypertension.

K O'Malley1, J P Cox, E O'Brien.   

Abstract

Event rates in relation to the number of elderly hypertensives treated were calculated from randomized analysis data from the 840 patients who completed the European Working Party on High Blood Pressure in the Elderly (EWPHE) trial. In all, the actively treated group had 29 fewer cardiovascular events per 1000 patient years. Putting this another way, treating 34 patients for 1 year would prevent one cardiovascular event. Moreover, as there were 14 fewer cardiovascular deaths and 11 fewer nonfatal strokes per 1000 patient years in the actively treated groups, we calculated that treating 71 or 91 elderly patients for 1 year would prevent one cardiovascular death or nonfatal stroke, respectively. Because of the higher baseline incidence of cardiovascular events in this study, there were greater gains in terms of absolute reductions in mortality and morbidity in treated elderly hypertensive patients than in younger patients in similar studies. Of the 840 patients who participated in the trial, 247 had systolic blood pressure greater than or equal to 160 mmHg and diastolic blood pressure less than or equal to 95 mmHg. In this group, blood pressure was reduced by 13/8 mmHg after 3 years in those randomized to active treatment compared to placebo. While patient numbers were insufficient to draw firm conclusions, their outcome on treatment was similar to that for patients on active treatment in the overall study. These results high-light the need for a rigorous assessment of the value of treating isolated systolic hypertension in the elderly.

Entities:  

Mesh:

Year:  1991        PMID: 2009248     DOI: 10.1007/bf00114228

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  8 in total

1.  Randomised trial of treatment of hypertension in elderly patients in primary care.

Authors:  J Coope; T S Warrender
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-01

2.  Evaluation of cardiovascular risk in the elderly: the Framingham study.

Authors:  W B Kannel; T Gordan
Journal:  Bull N Y Acad Med       Date:  1978-06

3.  Perspectives on systolic hypertension. The Framingham study.

Authors:  W B Kannel; T R Dawber; D L McGee
Journal:  Circulation       Date:  1980-06       Impact factor: 29.690

4.  Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.

Authors:  A Amery; W Birkenhäger; P Brixko; C Bulpitt; D Clement; M Deruyttere; A De Schaepdryver; C Dollery; R Fagard; F Forette
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

5.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

6.  Efficacy of antihypertensive drug treatment according to age, sex, blood pressure, and previous cardiovascular disease in patients over the age of 60.

Authors:  A Amery; W Birkenhäger; R Brixko; C Bulpitt; D Clement; M Deruyttere; A De Schaepdryver; C Dollery; R Fagard; F Forette
Journal:  Lancet       Date:  1986-09-13       Impact factor: 79.321

Review 7.  Treatment of elderly hypertensives: results and implications of recent trials.

Authors:  J P Cox; E T O'Brien; K O'Malley
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

8.  Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone.

Authors:  S B Hulley; C D Furberg; B Gurland; R McDonald; H M Perry; H W Schnaper; J A Schoenberger; W M Smith; T M Vogt
Journal:  Am J Cardiol       Date:  1985-12-01       Impact factor: 2.778

  8 in total
  5 in total

Review 1.  Treatment of hypertension in the elderly--the end of the story?

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1992-12       Impact factor: 3.727

Review 2.  Management of isolated systolic hypertension.

Authors:  A Tonkin; L Wing
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 3.  Pharmacotherapy for hypertension-induced left ventricular hypertrophy.

Authors:  Leire Leache; Marta Gutiérrez-Valencia; Rosa M Finizola; Elizabeth Infante; Bartolome Finizola; Jordi Pardo Pardo; Yris Flores; Ricardo Granero; Kaduo J Arai
Journal:  Cochrane Database Syst Rev       Date:  2021-10-10

4.  Pharmacotherapy for hypertension in adults 60 years or older.

Authors:  Vijaya M Musini; Aaron M Tejani; Ken Bassett; Lorri Puil; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

Review 5.  First-line drugs for hypertension.

Authors:  James M Wright; Vijaya M Musini; Rupam Gill
Journal:  Cochrane Database Syst Rev       Date:  2018-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.